Last update 01 Nov 2024
Mazdutide
Last update 01 Nov 2024
Overview
Basic Info
Drug Type Synthetic peptide |
Synonyms IBI-362, IBI362, LY 3305677 + [3] |
Target |
Mechanism GCGR agonists(Glucagon receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Login to view timeline
Gene Sequence
Sequence Code 1191632876
Source: *****
Related
34
Clinical Trials associated with MazdutideA Clinical Efficacy Study of Mazdutide in the Treatment of Polycystic Ovary Syndrome
A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of IBI362 in Chinese Obese Adolescent Subjects
评估IBI362在中国青少年肥胖受试者中多次给药的安全性、耐受性和药代动力学的随机、双盲、安慰剂对照的研究
[Translation] A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of IBI362 after repeated dosing in obese Chinese adolescent subjects
100 Clinical Results associated with Mazdutide
Login to view more data
100 Translational Medicine associated with Mazdutide
Login to view more data
100 Patents (Medical) associated with Mazdutide
Login to view more data
11
Literatures (Medical) associated with Mazdutide01 Dec 2024METABOLISM-CLINICAL AND EXPERIMENTAL
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials
Article
Author: Li, Mengting ; Cao, Weiling ; Zheng, Guimei ; Deng, Weishang ; Xie, Zeyu ; Liang, Zhuoru
PURPOSE:
This study aimed to provide evidence-based support and a reference for the efficacy and safety of seven glucagon-like peptide-1 (GLP-1) receptor agonists and polyagonists for weight loss in patients with obesity or overweight through a network meta-analysis.
METHODS:
Relevant randomized controlled trials (RCTs) with an intervention duration of at least 16 weeks assessing seven GLP-1 receptor agonists and polyagonists (mazdutide, 6 or 4.5 mg; retatrutide, 12 or 8 mg; tirzepatide, 15 or 10 mg; liraglutide, 3.0 mg; semaglutide, 2.4 mg; orforglipron, 45 or 36 mg; and beinaglutide, 0.2 mg) in patient with obesity or overweight was searched using three databases (Cochrane Library, PubMed, and Embase) from creation to August 30, 2024. The primary outcome was the percentage change in body weight from baseline. Secondary outcomes included changes in waist circumference, hemoglobin A1c, and fasting plasma glucose level from baseline; adverse events, serious adverse events, adverse event withdrawal, and hypoglycemic events. We conducted a frequentist random-effects network meta-analysis to analyze the data extracted from the RCTs using Stata 16.1 software.
RESULTS:
Twenty-seven RCTs of seven GLP-1 receptor agonists and polyagonists and 15,584 patients were included in the network meta-analysis. In terms of efficacy, compared with placebo, retatrutide 12 mg (-22.10 % in body weight and - 17.00 cm in waist circumference), retatrutide 8 mg (-20.70 % and - 15.90 cm), and tirzepatide 15 mg (-16.53 % and - 13.23 cm) were the three most efficacious treatments for reducing body weight and waist circumference. However, these treatments were less effective in patients with type 2 diabetes mellitus (T2DM). In addition, patients with a high body mass index (BMI) or longer treatment cycles exhibited significantly greater weight loss than those with a low BMI or shorter treatment cycles. In terms of safety, patients without T2DM had a higher incidence of adverse events than those with T2DM. None of the interventions increased the incidence of serious adverse or hypoglycemic events (˂54 mg/dL). There was no significant difference in the incidence of adverse event withdrawal for all interventions in head-to-head comparisons. In addition, disparities in race, BMI, and treatment cycles did not significantly increase the incidence of adverse events. Finally, the sensitivity and publication bias analyses indicated that the basic analysis results were reliable.
CONCLUSION:
Retatrutide (both doses) and tirzepatide exhibited superior efficacy compared to other GLP-1 receptor agonists and polyagonists in reducing body weight and waist circumference. Patients without T2DM, those with a high BMI, and individuals undergoing longer treatment cycles demonstrated significantly greater weight loss and reductions in waist circumference. Dual or triple receptor agonists (GLP-1 plus glucose-dependent insulinotropic polypeptide and/or Glucagon receptor) are more effective for weight loss than GLP-1 receptor agonists.
02 May 2024EXPERT OPINION ON PHARMACOTHERAPY
Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?
Review
Author: Melson, Eka ; Gogineni, Prathima ; Davies, Melanie ; Papamargaritis, Dimitris
INTRODUCTION:
Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have changed the landscape of type 2 diabetes (T2D) management due to their cardio-renal benefits, their glucose-lowering efficacy and weight loss (WL) maintenance. However, the response to GLP-1 RA monotherapy is heterogeneous. Additionally, the majority of GLP-1 RAs are injectable treatments. Oral GLP-1 RAs and injectable combinations of GLP-1 with other entero-pancreatic hormones (glucose-dependent insulinotropic polypeptide (GIP), glucagon and amylin) are under development for T2D and obesity management.
AREAS COVERED:
Herein, we review the data on (i) oral GLP-1 RAs (oral semaglutide 25/50 mg and orforglipron) and (ii) dual/triple agonists (tirzepatide, cagrilintide 2.4 mg/semaglutide 2.4 mg, survodutide, mazdutide, retatrutide) that have recently completed phase 3 trials for T2D or are currently in phase 3 clinical trials. Tirzepatide is the first approved dual agonist (GLP-1/GIP) for T2D and obesity management.
EXPERT OPINION:
We are in a new era in T2D management where entero-pancreatic hormone-based treatments can result in ≥15% WL and euglycemia for many people with T2D. Multiple molecules with different mechanisms of action are under development for T2D, obesity and other metabolic complications. Data on their cardio-renal benefits, long-term efficacy and safety as well as their cost-effectiveness will better inform their position in treatment algorithms.
01 Jan 2024Diabetes care
Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Article
Author: Wang, Xiaoyun ; Cheng, Zhifeng ; Jin, Ping ; Qian, Lei ; Ye, Shandong ; Yang, Wenying ; Gu, Xuejiang ; Zhang, Xin ; Gan, Shenglian ; Ma, Jianhua ; Deng, Huan ; Wang, Guixia ; Shi, Bimin ; Sun, Juan ; Li, Haoyu ; Ma, Guoqing ; Li, Li ; Ma, Qingyang ; Liu, Dexue ; Ji, Linong ; An, Pei ; Zhang, Bo ; Jiang, Hongwei ; Yu, Ting ; Chen, Ji ; Yi, Jianjun
OBJECTIVE:
We conducted a randomized, double-blind, placebo-controlled phase 2 trial to evaluate the efficacy and safety of mazdutide, a once-weekly glucagon-like peptide 1 and glucagon receptor dual agonist, in Chinese patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS:
Adults with type 2 diabetes inadequately controlled with diet and exercise alone or with stable metformin (glycated hemoglobin A1c [HbA1c] 7.0–10.5% [53–91 mmol/mol]) were randomly assigned to receive 3 mg mazdutide (n = 51), 4.5 mg mazdutide (n = 49), 6 mg mazdutide (n = 49), 1.5 mg open-label dulaglutide (n = 50), or placebo (n = 51) subcutaneously for 20 weeks. The primary outcome was change in HbA1c from baseline to week 20.
RESULTS:
Mean changes in HbA1c from baseline to week 20 ranged from −1.41% to −1.67% with mazdutide (−1.35% with dulaglutide and 0.03% with placebo; all P < 0.0001 vs. placebo). Mean percent changes in body weight from baseline to week 20 were dose dependent and up to −7.1% with mazdutide (−2.7% with dulaglutide and −1.4% with placebo). At week 20, participants receiving mazdutide were more likely to achieve HbA1c targets of <7.0% (53 mmol/mol) and ≤6.5% (48 mmol/mol) and body weight loss from baseline of ≥5% and ≥10% compared with placebo-treated participants. The most common adverse events with mazdutide included diarrhea (36%), decreased appetite (29%), nausea (23%), vomiting (14%), and hypoglycemia (10% [8% with placebo]).
CONCLUSIONS:
In Chinese patients with type 2 diabetes, mazdutide dosed up to 6 mg was generally safe and demonstrated clinically meaningful HbA1c and body weight reductions.
53
News (Medical) associated with Mazdutide19 Sep 2024
License out/inDrug Approval
12 Sep 2024
12 Sep 2024
Clinical ResultPhase 3VaccineDrug Approval
100 Deals associated with Mazdutide
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Mellitus, Type 2 | NDA/BLA | CN | 01 Aug 2024 | |
| Obesity | NDA/BLA | CN | 07 Feb 2024 | |
| Early-onset type II diabetes | Phase 3 | CN | 29 Feb 2024 | |
| Renal Insufficiency | Phase 1 | CN | 05 May 2023 | |
| Nonalcoholic Steatohepatitis | IND Approval | CN | 22 Mar 2023 | |
| Hyperuricemia | Preclinical | CN | 12 Jul 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
GLORY-1 (NEWS) Manual  | Phase 3 | 610 | ytytjwosfu(heqylexyqz) = ofjsohdlnk luuyakhbeg (mkssozztfu ) View more | Positive | 13 Sep 2024 | ||
(4 mg) | arhndfbmgw(vgmtvstkca) = qrmepvqflq kfkzmneked (rlfczihifr ) View more | ||||||
Phase 3 | 731 | mazdutide 4mg | ekzqmehxht(vmvdbzxljx) = qwpgikjhdh cwhvhqshrr (quxhczbelm ) View more | Positive | 11 Sep 2024 | ||
mazdutide 6mg | ekzqmehxht(vmvdbzxljx) = rrlpwyvphu cwhvhqshrr (quxhczbelm ) View more | ||||||
NCT05623839 (EASD2024) Manual | Phase 1 | 32 | (cohort 1) | chqwuqavvc(noqexuzaph) = nfnrgcswtu xxlsykqioa (oranqvekak ) View more | Positive | 09 Sep 2024 | |
(cohort 2) | chqwuqavvc(noqexuzaph) = fzagubuvop xxlsykqioa (oranqvekak ) View more | ||||||
Phase 3 | - | Mazdutide 4 mg | nmwwgeksol(fcnsatlacd) = dkbqplrwhw hfvezewmas (ychdtttqbh ) Met | Positive | 21 Jul 2024 | ||
Mazdutide 6 mg | nmwwgeksol(fcnsatlacd) = oithdupqvn hfvezewmas (ychdtttqbh ) Met | ||||||
Phase 3 | 69 | Mazdutide 4mg | hqtihvjiua(mmlkcmuwza) = dbozjwwpdu nvepjuybrr (itmlanwqmr ) View more | Positive | 21 Jun 2024 | ||
Mazdutide 6mg | hqtihvjiua(mmlkcmuwza) = ospdgylnlk nvepjuybrr (itmlanwqmr ) View more | ||||||
NCT04904913 (ADA2024) Manual | Phase 2 | 80 | huoftdbnjj(gnfcxgdcai) = wcmqlcapeq pkytrkmgea (zfgpmjkhaf ) View more | Positive | 20 Jun 2024 | ||
Placebo | huoftdbnjj(gnfcxgdcai) = znqftejmpo pkytrkmgea (zfgpmjkhaf ) View more | ||||||
Phase 3 | 610 | mazdutide 4 mg | cnzlrzumik(mcpbfzcowg) = hrfsxcuihz dgbssuvftv (mpjymwcsbi, 0.538) Met View more | Positive | 14 Jun 2024 | ||
mazdutide 6 mg | cnzlrzumik(mcpbfzcowg) = aznitvunnw dgbssuvftv (mpjymwcsbi, 0.558) Met View more | ||||||
Phase 3 | 731 | mazdutide 4.0 mg | uupmryptpe(pwqmxmglyj) = the superiority test was further performed, and both mazdutide 4.0 mg and 6.0 mg achieved superiority to dulaglutide 1.5 mg. onoexxsgnj (qwenktwomx ) Met View more | Superior | 09 May 2024 | ||
mazdutide 6.0 mg | |||||||
Phase 3 | 610 | 玛仕度肽 4 mg | zuuixtcaeb(dfotacfgqp) = 主要研究终点顺利达成：玛仕度肽 4 mg和6 mg组受试者治疗32周后体重相对基线的百分比变化显著优于安慰剂组 gcpiciglzw (tdmvhykigw ) Met View more | Positive | 09 Jan 2024 | ||
玛仕度肽 6 mg | |||||||
NCT04965506 (Literature) Manual | Phase 2 | 250 | Mazdutide 3 mg | zshsidqdyx(jprtmegpfi) = rjnodrghhq mjjkvpgwhx (egnmorgkhe ) View more | Positive | 09 Nov 2023 | |
Mazdutide 4.5 mg | zshsidqdyx(jprtmegpfi) = ofnjhmppzl mjjkvpgwhx (egnmorgkhe ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free